Karyopharm Therapeutics
Keyur Patel is a seasoned professional in the pharmaceutical industry, currently serving as a Senior Scientist - CMC at Karyopharm Therapeutics Inc. since January 2021, where responsibilities include overseeing contract manufacturing organizations for drug substance and drug product releases, stability testing, and analytical testing. Prior experience includes roles at Takeda as a Scientist - CMC and Senior QC Analyst, leading testing efforts for drug releases and stability while mentoring junior analysts, as well as positions at Shire, FrieslandCampina, and Norwich Pharmaceuticals, where expertise in quality control and analytical chemistry was developed. Keyur Patel holds a Master of Science in Pharmaceutical Manufacturing Engineering from Stevens Institute of Technology and a Bachelor of Pharmacy from Rajiv Gandhi University of Health Sciences.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).